ENANTA PHARMACEUTICALS INC: FARALLON CAPITAL MANAGEMENT, L.L.C. amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Farallon Capital Management amended its Schedule 13G stake filing for Enanta Pharmaceuticals, disclosing the change to the SEC under accession number 0000908834-26-000532. The filing updates the investment firm's previously reported position in the clinical-stage biotech, though the amended disclosure did not specify a revised share count or percentage in the headline. The revision matters because 13G amendments signal shifts in passive or institutional ownership that can influence Enanta's shareholder base and governance dynamics. Investors will watch for the detailed ownership figures in the full filing and any subsequent 13F disclosures for confirmation of Farallon's current stake.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Farallon Capital Management, L.L.C., Enanta Pharmaceuticals Inc